title: Endometritis does not predict reproductive morbidity after pelvic inflammatory disease.
abstract: OBJECTIVE
  We investigated the association between endometritis and reproductive morbidity.
  
  
  METHODS
  Participants were 614 women in the PID Evaluation and Clinical Health (PEACH) Study with pelvic pain, pelvic organ tenderness, and leukorrhea, mucopurulent cervicitis, or untreated cervicitis. We compared women with endometritis (>or=5 neutrophils or >or=2 plasma cells), Neisseria gonorrhoeae or Chlamydia trachomatis upper genital tract infection (UGTI) or both to women without endometritis/UGTI for outcomes of pregnancy, infertility, recurrent pelvic inflammatory disease (PID), and chronic pelvic pain (CPP), adjusting for age, race, education, PID history, and baseline infertility.
  
  
  RESULTS
  Endometritis/UGTI was not associated with reduced pregnancy (odds ratio [OR] 0.8, 95% CI 0.6-1.2) or elevated infertility (OR 1.0, 95% CI 0.6-1.6), recurrent PID (OR 0.6, 95% CI 0.4-0.9), or CPP (OR 0.6, 95% CI 0.4-0.9). PEACH participants with and without endometritis/UGTI had higher age- and race-specific pregnancy rates than 1997 national rates.
  
  
  CONCLUSIONS
  Among women with clinically suspected mild-to-moderate PID treated with standard antibiotics, endometritis/UGTI was not associated with reproductive morbidity.
authors.affiliation: University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA 15261, USA. clcst10@pitt.edu
authors.forename: Catherine L
authors.initials: CL
authors.lastname: Haggerty
authors.forename: Roberta B
authors.initials: RB
authors.lastname: Ness
authors.forename: Antonio
authors.initials: A
authors.lastname: Amortegui
authors.forename: Susan L
authors.initials: SL
authors.lastname: Hendrix
authors.forename: Sharon L
authors.initials: SL
authors.lastname: Hillier
authors.forename: Robert L
authors.initials: RL
authors.lastname: Holley
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Peipert
authors.forename: Hugh
authors.initials: H
authors.lastname: Randall
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Sondheimer
authors.forename: David E
authors.initials: DE
authors.lastname: Soper
authors.forename: Richard L
authors.initials: RL
authors.lastname: Sweet
authors.forename: Guiliana
authors.initials: G
authors.lastname: Trucco
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001421:Bacteria, Anaerobic; D001424:Bacterial Infections / Q000150:complications; D002440:Cefoxitin / Q000008:administration & dosage / Q000627:therapeutic use; D002690:Chlamydia Infections / Q000150:complications; D004318:Doxycycline / Q000008:administration & dosage / Q000627:therapeutic use; D004716:Endometritis / Q000150:complications*; D004717:Endometrium / Q000382:microbiology / Q000473:pathology; D005260:Female; D006069:Gonorrhea / Q000150:complications; D006801:Humans; D007247:Infertility, Female / Q000209:etiology*; D016017:Odds Ratio; D000292:Pelvic Inflammatory Disease / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D011247:Pregnancy; D011339:Probenecid / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D002440:Cefoxitin; D004318:Doxycycline; D011339:Probenecid